Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2010

View Archived Issues

Promising clinical effects with topical miltefosine and clobetasol in cutaneous mastocytosis

Novel delivery system for targeted radiotherapy of breast cancer shows promise in vitro

Smo receptor antagonists described by Amgen for cancer therapy

Xoma summarizes clinical development of its lead product XOMA-052

GenVec reports key event in phase III trial of TNFerade in advanced pancreatic cancer

Enrollment completed in phase II portion of phase II/III trial of Taksta

Circassia begins phase II trials of ToleroMune in house dust mite and cat allergies

EMEA Pediatric Committee grants product-specific waivers for StemEx

Durect initiates pivotal phase III Posidur trial

Acceleron adds two novel programs to development pipeline

Verona Pharma provides pipeline update

Pfizer obtains approval for Xalacom for glaucoma and ocular hypertension

Sunitinib activity limited in patients with squamous cell carcinoma of the head and neck

Novartis receives Japanese approval for Equa, Exforge and Afinitor

Daiichi granted Japanese approval to manufacture and market Rezaltas for hypertension

Cleveland BioLabs initiates dosing in phase Ib trial of CBLB-502

Siga discloses antiviral compounds for the treatment of dengue fever

Novel S1P1 receptor agonists in early development at Arena

NeuroSearch presents nAChR ligands for the treatment of cognitive disorders

Nycomed pays milestone payment to Immunomedics for veltuzumab

Novo Nordisk obtains approval in Japan for Victoza for type 2 diabetes

Matrix Laboratories describes PDE IV inhibitors for asthma therapy

PTC starts additional ataluren study in Duchenne/Becker muscular dystrophy

Spear Therapeutics discloses novel compounds for cancer treatment

Phase II data show ixabepilone to be safe and efficacious in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...